Company Description
Merck helps those who are hooked on hamburgers. Drugs treating ailments associated with bad eating habits -- high cholesterol, hypertension, and...
Key Merck Financials
| Company Type | Public - NYSE: MRK Main Headquarters |
|---|---|
| Fiscal Year-End | December |
| 2007 Sales (mil.) | $24,197.7 |
| 2007 Employees | 59,800 |
More Merck Financials (11 pages)
Latest Merck Jobs jobs by Indeed
Rankings
- #101 in FORTUNE 500
- S&P 500
- Dow Jones Industrials
- #59 in FT Global 500
Competition
Competitive Landscape for Pharmaceutical Manufacture and Sale
The industry is marked by rapid advances in scientific knowledge that produce ever-more effective medicines. Profitability is determined mainly by the ability to discover new drugs....
Read more about Merck's competition across multiple industries
Top Merck Competitors
Sponsored Links
The Business DirectoryTrading Toolbox
Merck Executives sponsored by genius.com
| Title | Name & Bio | Contact |
|---|---|---|
| Chairman, President, and CEO | Richard T. (Dick) Clark | Network | E-mail |
| Chief Marketing Officer | Wendy L. Yarno | Network | E-mail |
| EVP Global Services, and Chief Information Officer | J. Chris Scalet | Network | E-mail |
| Are You Listed On Hoover's? | ||
|---|---|---|
| Hoover's subscribers also get access to information on people who have self-listed with this company. Subscribers also have the option to add themselves to this company record. |
Tools from our advertising partners:
Current Merck News
- [DIAG]-International report [AHC Newsletters] (03 Jul 2008 00:01:00 EDT)
- [DIAG]-New ventures [AHC Newsletters] (03 Jul 2008 00:01:00 EDT)
- BioWorld Today July 3, 2008 [BioWorld Today] (03 Jul 2008 00:01:00 EDT)
Latest Merck Video
-
Merck Briefs Analysts (4:30)
12/11/07 10:25ET - Merck CEO Richard Clark discusses his outlook for the pharmaceuticals giant with CNBC's Mike Huckman.
Latest Industry Video
-
Rx For Cheap Drugs (4:04)
07/23/07 5:20PM ET - Miller Tabak & Co. Pharmaceuticals Analyst Les Fundleyder and Bain & Company Partner Tim Van Biesen discuss patent expirations affecting U.S. drug costs.